Meeting
2023 ASCO Annual Meeting
OMNIA-2: Phase I/II study of ANV419, an IL-2R-βγ targeted antibody-IL-2 fusion protein, in patients with relapsed or refractory multiple myeloma.
Authors
Dagmar Hess
Kantonsspital St. Gallen, St. Gallen, Switzerland
Dagmar Hess , Katrine Fladeland Iversen , Maria-Victoria Mateos , Thomas Pabst , Laura Rosiñol , Jana Kovacikova , Sangeeta Jethwa Schnetzler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT05641324
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS8068)
DOI
10.1200/JCO.2023.41.16_suppl.TPS8068
Abstract #
TPS8068
Poster Bd #
57b
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Preclinical assessment of IPH6501, a first-in-class IL2v-armed tetraspecific NK cell engager directed against CD20 for R/R B-NHL, in comparison with a CD20-targeting T cell engager.
First Author: Olivier Demaria
Poster
2017 ASCO Annual Meeting
Daratumumab, lenalidomide, and dexamethasone (DRd) vs lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (POLLUX).
First Author: Nizar J. Bahlis
Poster
2015 ASCO Annual Meeting
Phase 1b interim results: Venetoclax (ABT-199/GDC-0199) in combination with bortezomib (BTZ) and dexamethasone (Dex) in relapsed/refractory (R/R) multiple myeloma (MM).
First Author: Cyrille Touzeau
Poster
2013 ASCO Annual Meeting
Results of a phase I/II study (NCT01365559) of carfilzomib (CFZ) replacing bortezomib (BTZ) in BTZ-containing regimens for BTZ-treated patients (pts) with relapsed and refractory multiple myeloma (MM).
First Author: James R. Berenson